Eli Lilly Boosts Sales Outlook as Obesity Drugs Drive Growth

Eli Lilly has delivered another stellar quarter with third-quarter earnings and revenue significantly surpassing analyst expectations, prompting the pharmaceutical giant to raise its full-year sales outlook. The company's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro continue to drive exceptional growth, demonstrating the expanding market for GLP-1 medications. This performance comes as Lilly solidifies its position as a leader in the rapidly growing obesity and diabetes treatment sector, even as it faces increasing competition and pricing pressures in the U.S. market.

Key Takeaways

• Revenue Outlook Raised: Eli Lilly now expects 2026 revenue between $91 billion and $92 billion, up from previous guidance of $85-87 billion, reflecting stronger-than-expected performance across its product portfolio.
• Mounjaro's Explosive Growth: The diabetes treatment generated $10.72 billion in worldwide revenue for the quarter, a 65% increase year-over-year, with international sales jumping an impressive 93%.
• Zepbound's Continued Expansion: The weight loss drug posted $5.35 billion in revenue, up 49% from the previous year, despite facing lower realized prices in the U.S. market.
• Foundayo's Mixed Debut: The newly launched obesity pill recorded $184 million in sales, falling short of analyst expectations of around $229 million, though prescriptions and new patients doubled from the previous quarter.
• Market Dominance: Lilly maintains a commanding 63% share of the U.S. obesity and diabetes drug market, significantly ahead of rival Novo Nordisk's 36.6% share.
• Strategic Expansion: The company is converting its profits into strategic acquisitions, recently agreeing to buy Merida Biosciences to develop new treatments for autoimmune and allergic diseases.

In-Depth Analysis

Eli Lilly's exceptional performance in the third quarter underscores the transformative potential of GLP-1 medications in treating metabolic disorders. The company's ability to maintain strong growth despite lower U.S. prices—resulting from a drug pricing agreement with the Trump administration—demonstrates the underlying strength of demand for these therapies. The expansion of Medicare coverage for obesity treatments through a temporary pilot program has further accelerated market access, creating additional growth opportunities.

The competitive landscape in the GLP-1 market remains intense, with Lilly holding a significant advantage over Novo Nordisk. However, the emergence of oral alternatives like Foundayo and Novo's competing pill suggests the market is evolving rapidly. Lilly's strategic focus on both injectable and oral formulations positions it well to capture diverse patient preferences and treatment needs.

Looking ahead, the obesity and diabetes treatment market appears poised for substantial expansion. CEO Dave Ricks estimates that only 3-10% of eligible patients currently access obesity care in the U.S., suggesting significant room for market growth. As Lilly continues to invest in research and development through strategic acquisitions like the Merida Biosciences deal, the company is well-positioned to maintain its leadership in this rapidly evolving therapeutic area.

Frequently Asked Questions

What factors are driving Eli Lilly's strong performance? Lilly's exceptional results are primarily driven by surging demand for its GLP-1 medications Mounjaro and Zepbound, expanded insurance coverage for obesity treatments, and successful international market expansion. The company's strategic acquisitions and diversified product portfolio further contribute to its growth trajectory.

How does Lilly's new obesity pill Foundayo compare to expectations? Foundayo's $184 million in third-quarter sales fell short of analyst expectations of around $229 million. However, prescriptions and new patients doubled from the previous quarter, indicating growing adoption. The pill faces competition from Novo Nordisk's oral obesity medication, launched earlier this year.

What is Lilly's market position in the obesity and diabetes drug sector? Lilly maintains a dominant 63% share of the U.S. obesity and diabetes drug market, compared to Novo Nordisk's 36.6%. Internationally, Lilly holds 58.4% of the market, with Novo controlling 41.6%. Seven out of ten U.S. prescriptions for injectable obesity and diabetes drugs are for Lilly medications.

Source: https://www.cnbc.com/2026/10/29/eli-lilly-lly-earnings-q3-2026.html